Prelude Capital Management, LLC Abb Vie Inc. Call Options Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $726,330 - $799,602	-7,100 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $29,348 - $39,272	-400 Reduced 5.33%	7,100 $697,000
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $2.17 Million - $3.29 Million	-33,600 Reduced 81.75%	7,500 $571,000
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $1.95 Million - $2.45 Million	27,100 Added 193.57%	41,100 $3.64 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $2.27 Million - $2.73 Million	-36,000 Reduced 72.0%	14,000 $1.06 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $3.28 Million - $4.19 Million	49,900 Added 49900.0%	50,000 $3.64 Million
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $7,784 - $9,601	100 New	100 $9,000
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $17,956 - $21,246	-200 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $18,402 - $24,642	200 New	200 $19,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.